LIVIVO - Search results -

Search results

Result 1 - 10 of total 28

Search options

Article ; Online: Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

2024 Volume 15, Issue 1, Page(s) 225

Language	English
Publishing date	2024-01-03
Publishing country	England
Document type	Published Erratum
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-44575-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Kinase overexpressing cancers responsive to drug withdrawal.

Amin, Amit Dipak / Rajan, Soumya S / Schatz, Jonathan H

Aging

2015 Volume 7, Issue 10, Page(s) 752–753

MeSH term(s)	Animals ; Antineoplastic Agents/administration & dosage ; Drug Resistance, Neoplasm ; Humans ; Neoplasms/drug therapy ; Neoplasms/enzymology ; Protein Kinase Inhibitors/administration & dosage
Chemical Substances	Antineoplastic Agents ; Protein Kinase Inhibitors
Language	English
Publishing date	2015-10
Publishing country	United States
Document type	Editorial
ISSN	1945-4589
ISSN (online)	1945-4589
DOI	10.18632/aging.100830
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: CRISPR genome editing of murine hematopoietic stem cells to create

Rajan, Soumya Sundara / Li, Lingxiao / Kweh, Mercedes F / Kunkalla, Kranthi / Amin, Amit Dipak / Agarwal, Nitin K / Vega, Francisco / Schatz, Jonathan H

Blood advances

2019 Volume 3, Issue 12, Page(s) 1788–1794

MeSH term(s)	Adolescent ; Anaplastic Lymphoma Kinase/metabolism ; Animals ; Bone Marrow/virology ; Cell Culture Techniques/methods ; Clustered Regularly Interspaced Short Palindromic Repeats/genetics ; Fetal Tissue Transplantation/methods ; Fetus/surgery ; Gene Editing/methods ; Hematopoietic Stem Cell Transplantation/methods ; Hematopoietic Stem Cell Transplantation/veterinary ; Hematopoietic Stem Cells/metabolism ; Humans ; Liver/surgery ; Lymphoma, T-Cell/genetics ; Lymphoma, T-Cell/surgery ; Lymphoma, T-Cell/veterinary ; Mice ; Mice, Inbred C57BL ; Models, Animal ; Nuclear Proteins/metabolism ; Oncogene Proteins, Fusion/genetics ; Receptor Protein-Tyrosine Kinases/metabolism ; Retroviridae Infections/complications ; Stem Cells/virology ; Young Adult
Chemical Substances	Nuclear Proteins ; Oncogene Proteins, Fusion ; nucleophosmin (117896-08-9) ; Alk protein, mouse (EC 2.7.10.1) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2019-06-12
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2018025247
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A global requirement for the HIR complex in the assembly of chromatin.

Amin, Amit Dipak / Vishnoi, Nidhi / Prochasson, Philippe

Biochimica et biophysica acta

2013 Volume 1819, Issue 3-4, Page(s) 264–276

Abstract: Due to its extensive length, DNA is packaged into a protective chromatin structure known as the nucleosome. In order to carry out various cellular functions, nucleosomes must be disassembled, allowing access to the underlying DNA, and subsequently ... ...

Abstract	Due to its extensive length, DNA is packaged into a protective chromatin structure known as the nucleosome. In order to carry out various cellular functions, nucleosomes must be disassembled, allowing access to the underlying DNA, and subsequently reassembled on completion of these processes. The assembly and disassembly of nucleosomes is dependent on the function of histone modifiers, chromatin remodelers and histone chaperones. In this review, we discuss the roles of an evolutionarily conserved histone chaperone known as the HIR/HIRA complex. In S. cerevisiae, the HIR complex is made up of the proteins Hir1, Hir2, Hir3 and Hpc2, which collectively act in transcriptional regulation, elongation, gene silencing, cellular senescence and even aging. This review presents an overview of the role of the HIR complex, in yeast as well as other organisms, in each of these processes, in order to give a better understanding of how nucleosome assembly is imperative for cellular homeostasis and genomic integrity. This article is part of a Special Issue entitled: Histone chaperones and Chromatin assembly.
MeSH term(s)	Animals ; Chromatin Assembly and Disassembly/physiology ; Gene Silencing/physiology ; Heterochromatin/genetics ; Heterochromatin/metabolism ; Histone Chaperones/physiology ; Humans ; Multiprotein Complexes/physiology ; Nucleosomes/metabolism ; Transcription, Genetic/physiology
Chemical Substances	Heterochromatin ; Histone Chaperones ; Multiprotein Complexes ; Nucleosomes
Language	English
Publishing date	2013-03
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	60-7
ISSN	1879-2596 ; 1879-260X ; 1872-8006 ; 1879-2642 ; 1879-2618 ; 1879-2650 ; 0006-3002 ; 0005-2728 ; 0005-2736 ; 0304-4165 ; 0167-4838 ; 1388-1981 ; 0167-4889 ; 0167-4781 ; 0304-419X ; 1570-9639 ; 0925-4439 ; 1874-9399
ISSN (online)	1879-2596 ; 1879-260X ; 1872-8006 ; 1879-2642 ; 1879-2618 ; 1879-2650
ISSN	0006-3002 ; 0005-2728 ; 0005-2736 ; 0304-4165 ; 0167-4838 ; 1388-1981 ; 0167-4889 ; 0167-4781 ; 0304-419X ; 1570-9639 ; 0925-4439 ; 1874-9399
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.247: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens.

Wang, Yiping / Fan, Joy Linyue / Melms, Johannes C / Amin, Amit Dipak / Georgis, Yohanna / Barrera, Irving / Ho, Patricia / Tagore, Somnath / Abril-Rodríguez, Gabriel / He, Siyu / Jin, Yinuo / Biermann, Jana / Hofree, Matan / Caprio, Lindsay / Berhe, Simon / Khan, Shaheer A / Henick, Brian S / Ribas, Antoni / Macosko, Evan Z /

Chen, Fei / Taylor, Alison M / Schwartz, Gary K / Carvajal, Richard D / Azizi, Elham / Izar, Benjamin

Nature genetics

2023 Volume 55, Issue 1, Page(s) 19–25

Abstract: Single-cell genomics enables dissection of tumor heterogeneity and molecular underpinnings of drug response at an unprecedented ... ...

Abstract	Single-cell genomics enables dissection of tumor heterogeneity and molecular underpinnings of drug response at an unprecedented resolution
MeSH term(s)	Humans ; Genomics/methods ; Gene Expression Profiling/methods ; Neoplasms/genetics ; Sequence Analysis, RNA/methods ; Whole Genome Sequencing
Language	English
Publishing date	2023-01-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	1108734-1
ISSN	1546-1718 ; 1061-4036
ISSN (online)	1546-1718
ISSN	1061-4036
DOI	10.1038/s41588-022-01268-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3613: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 46: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Nature communications

2023 Volume 14, Issue 1, Page(s) 8435

Abstract: We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined ... ...

Abstract	We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary endpoint of disease-free survival (DFS) regardless of treatment assignment and the prespecified exploratory analysis of DFS in each arm of the trial. DFS at 2 and 3 years across patients in both arms of the trial were 73% (95% CI: 62.1-84.5) and 65% (95% CI: 52.5-76.9) respectively. For the exploratory endpoint of DFS in each arm of the trial, three-year DFS was 63% (95% CI: 46.0-80.4) in the durvalumab monotherapy arm compared to 67% (95% CI: 49.6-83.4) in the dual therapy arm. In addition, we report post hoc exploratory analysis of progression-free survival as well as molecular correlates of response and recurrence through high-plex immunophenotyping of sequentially collected peripheral blood and gene expression profiles from resected tumors in both treatment arms. Together, our results contribute to the evolving landscape of neoadjuvant treatment regimens for NSCLC and identify easily measurable potential biomarkers of response and recurrence.
MeSH term(s)	Humans ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Neoadjuvant Therapy ; Small Cell Lung Carcinoma/drug therapy ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase II as Topic
Chemical Substances	Antibodies, Monoclonal ; durvalumab (28X28X9OKV)
Language	English
Publishing date	2023-12-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-44195-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: A global requirement for the HIR complex in the assembly of chromatin

Amin, Amit Dipak / Vishnoi, Nidhi / Prochasson, Philippe

BBA - Gene Regulatory Mechanisms. 2012 , v. 1819, no. 3-4

2012

Abstract	Due to its extensive length, DNA is packaged into a protective chromatin structure known as the nucleosome. In order to carry out various cellular functions, nucleosomes must be disassembled, allowing access to the underlying DNA, and subsequently reassembled on completion of these processes. The assembly and disassembly of nucleosomes is dependent on the function of histone modifiers, chromatin remodelers and histone chaperones. In this review, we discuss the roles of an evolutionarily conserved histone chaperone known as the HIR/HIRA complex. In S. cerevisiae, the HIR complex is made up of the proteins Hir1, Hir2, Hir3 and Hpc2, which collectively act in transcriptional regulation, elongation, gene silencing, cellular senescence and even aging. This review presents an overview of the role of the HIR complex, in yeast as well as other organisms, in each of these processes, in order to give a better understanding of how nucleosome assembly is imperative for cellular homeostasis and genomic integrity. This article is part of a Special Issue entitled: Histone chaperones and Chromatin assembly.
Keywords	DNA ; gene silencing ; histones ; homeostasis ; nucleosomes ; senescence ; transcription (genetics) ; yeasts
Language	English
Dates of publication	2012-03
Size	p. 264-276.
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	2406725-8
ISSN	1876-4320 ; 1874-9399
ISSN (online)	1876-4320
ISSN	1874-9399
DOI	10.1016/j.bbagrm.2011.07.008
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.

Amin, Amit Dipak / Rajan, Soumya S / Groysman, Matthew J / Pongtornpipat, Praechompoo / Schatz, Jonathan H

Biomarkers in cancer

2015 Volume 7, Issue Suppl 2, Page(s) 25–32

Abstract: Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel ... ...

Abstract	Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel pathways, but durable benefit to patients remains elusive in most clinical scenarios. Now, recent studies suggest a third approach may be available in some cases-exploitation of oncogene overexpression that may arise to promote resistance. Here, we discuss the importance of maintaining oncogenic signaling at "just-right" levels in cells, with too much signaling, or oncogene overdose, being potentially as detrimental as too little. This is highlighted in particular by recent studies of mutant-BRAF in melanoma and the fusion kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) in anaplastic large cell lymphoma. Oncogene overdose may be exploitable to prolong tumor control through intermittent dosing in some cases, and studies of acute lymphoid leukemias suggest that it may be specifically pharmacologically inducible.
Language	English
Publishing date	2015-12-15
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2592049-2
ISSN	1179-299X
ISSN	1179-299X
DOI	10.4137/BIC.S29326
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

Amin, Amit Dipak / Peters, Tara L / Li, Lingxiao / Rajan, Soumya Sundara / Choudhari, Ramesh / Puvvada, Soham D / Schatz, Jonathan H

Cold Spring Harbor molecular case studies

2017 Volume 3, Issue 3, Page(s) a001719

Abstract: Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate pathogenic ...

Abstract	Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate pathogenic mechanisms, however, the five-drug chemoimmunotherapy combination R-CHOP remains the frontline standard treatment. This has not changed in 15 years, since the anti-CD20 monoclonal antibody rituximab was added to the CHOP backbone, which first entered use in the 1970s. At least a third of patients are not cured by R-CHOP, and relapsed or refractory DLBCL is fatal in ∼90%. Targeted small-molecule inhibitors against distinct molecular pathways activated in different subgroups of DLBCL have so far translated poorly into the clinic, justifying the ongoing reliance on R-CHOP and other long-established chemotherapy-driven combinations. New drugs and improved identification of biomarkers in real time, however, show potential to change the situation eventually, despite some recent setbacks. Here, we review established and putative molecular drivers of DLBCL identified through large-scale genomics, highlighting among other things the care that must be taken when differentiating drivers from passengers, which is influenced by the promiscuity of activation-induced cytidine deaminase. Furthermore, we discuss why, despite having so much genomic data available, it has been difficult to move toward personalized medicine for this umbrella disorder and some steps that may be taken to hasten the process.
MeSH term(s)	Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Gene Expression Profiling/methods ; Genomics ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/genetics ; Precision Medicine ; Prednisone/administration & dosage ; Rituximab/administration & dosage ; Vincristine/administration & dosage
Chemical Substances	Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2017-05-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2835759-0
ISSN	2373-2873
ISSN	2373-2873
DOI	10.1101/mcs.a001719
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.

Liu, Guangbo / Pei, Fen / Yang, Fengqing / Li, Lingxiao / Amin, Amit Dipak / Liu, Songnian / Buchan, J Ross / Cho, William C

International journal of molecular sciences

2017 Volume 18, Issue 2

Abstract: Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant further investigation into the molecular ... ...

Abstract	Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant further investigation into the molecular mechanisms of NSCLC and the development of new, more efficacious therapeutics. The processes of autophagy and apoptosis, which induce degradation of proteins and organelles or cell death upon cellular stress, are crucial in the pathophysiology of NSCLC. The close interplay between autophagy and apoptosis through shared signaling pathways complicates our understanding of how NSCLC pathophysiology is regulated. The apoptotic effect of autophagy is controversial as both inhibitory and stimulatory effects have been reported in NSCLC. In addition, crosstalk of proteins regulating both autophagy and apoptosis exists. Here, we review the recent advances of the relationship between autophagy and apoptosis in NSCLC, aiming to provide few insights into the discovery of novel pathogenic factors and the development of new cancer therapeutics.
MeSH term(s)	Animals ; Apoptosis/drug effects ; Apoptosis/genetics ; Apoptosis Regulatory Proteins/metabolism ; Autophagy/drug effects ; Autophagy/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/therapy ; Cell Communication ; Endoplasmic Reticulum Stress/drug effects ; Energy Metabolism ; Genetic Variation ; Humans ; Immunotherapy ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/therapy ; MAP Kinase Signaling System ; Molecular Targeted Therapy ; Protein Binding ; Risk Factors ; Signal Transduction ; Stress, Physiological ; TOR Serine-Threonine Kinases/metabolism
Chemical Substances	Apoptosis Regulatory Proteins ; TOR Serine-Threonine Kinases (EC 2.7.11.1)
Language	English
Publishing date	2017-02-10
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms18020367
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito